未平仓空仓比减少最大的10只股票 前10大未平仓空仓比 | 股票名称 | 前次空仓数 | 本次空仓数 | 最新空仓比↓ | | --- | --- | --- | --- | | 万科企业(02202) | 4.33 亿股 | 4.94 亿股 | 22.40% | | 中远海控(01919) | 4.75 亿股 | 4.88 亿股 | 16.93% | | 中兴通讯(00763) | 1.19 亿股 | 1.18 亿股 | 15.67% | | 恒瑞医药(01276) | 4223.83 万股 | 4039.41 万股 | 15.64% | | 中国平安(02318) | 10.24 亿股 | 9.94 亿股 | 13.35% | | 东方电气(01072) | 4756.82 万股 | 5309.73 万股 | 13.01% | | 紫金矿业(02899) | 6.74 亿股 | 6.65 亿股 | 11.10% | | 哔哩哔哩-W(09626) | 4086.86 万股 | 4355.12 万股 | 10.53% | | 锦欣生殖(01951) | 2.85 亿股 | 2.77 亿股 | 10.11% ...

朱国新是恒瑞医药今年引入的第二位跨国药企核心高管，或将 成为这家公司的7号人物。 作者： 刘晓诺 封图：图虫创意 想出海的"医药一哥"，正不断引进有海外经验的"船长"和"大副"。 2025年12月3日，恒瑞医药（600276.SH/01276.HK）宣布提名聘任朱国新为高级副总裁。公开信 息显示，加入恒瑞之前，朱国新曾是跨国公司礼来的新药研发中心副总裁。 胡新辉任副总裁与首席技术官。据公开资料，2005—2018年，胡新辉曾在葛兰素史克、默沙东、 强生、罗氏上海研发中心等多家跨国药企任职。此后，他先后担任云顶新耀（01952.HK）首席技 术官、凯莱英（002821.SZ/06821.HK）首席技术官兼首席商务官。 孙志刚任副总裁与首席质量官。加入恒瑞医药之前，他是绿叶制药（02186.HK）集团高级副总 裁。他曾在美国FDA工作近12年，负责药品质量审评和GMP现场检查等工作。 尹航任副总裁与肿瘤事业部总经理。他曾任职于诺和诺德，2019年加入礼来中国，2021年8月起任 礼来肿瘤事业部副总裁，直至2025年9月离任。 此外，10月10日，恒瑞医药控股的互联网医疗公司医朵云也迎来新高管：前阿斯利康中国副总裁 ...

智通财经APP获悉，截止12月5日收盘，东北电气(00042)、弘业期货(03678)、中石化油服(01033)分列 AH溢价率前三位，溢价率分别为900.00%、268.44%、264.47%；宁德时代(03750)、招商银行(03968)、 恒瑞医药(01276)分列AH溢价率末三位，溢价率分别为-4.97%、-3.09%、0.15%。其中东北电气 (00042)、广和通(00638)、京城机电股份(00187)的偏离值位居前三，分别为33.66%、30.36%、23.74%； 另外，广汽集团(02238)、江苏宁沪高速公路(00177)、深圳高速公路股份(00548)的偏离值位居后三，分 别为-24.07%、-18.32%、-11.27%。 前十大AH股溢价率排行 后十大AH股偏离值排行 后十大AH股溢价率排行 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↑ | | --- | --- | --- | --- | --- | | 广汽集团(02238) | 3.990 | 8.57 | 157.39% | -24.07% | | 江苏宁沪高速公路 | 10.240 | 12.45 | ...

一位上市创新药企董事长对经济观察报说："朱国新应该算华人在跨国药企中位子比较高的人了。这个人口碑相当不错，年纪也正当年，应该是1968-1969年 出生。我觉得对今天的恒瑞是一个很好的选择。" 朱国新是恒瑞医药今年引入的第二位跨国药企核心高管。4月，冯佶成为恒瑞医药近年引进的首位跨国药企中国区"一把手"。 她生于1970年，曾就职于上海仁济医院、诺华和安万特。此后，冯佶在阿斯利康工作20多年，曾担任中国区总经理、亚洲区区域副总裁、全球商业洞察与卓 越业务高级副总裁等职务。 10月，恒瑞医药还官宣了三位新任副总裁，均有海外背景： 胡新辉任副总裁与首席技术官。据公开资料，2005—2018年，胡新辉曾在葛兰素史克、默沙东、强生、罗氏上海研发中心等多家跨国药企任职。此后，他先 后担任云顶新耀（01952.HK）首席技术官、凯莱英（002821.SZ/06821.HK）首席技术官兼首席商务官。 经济观察报 记者 刘晓诺 想出海的"医药一哥"，正不断引进有海外经验的"船长"和"大副"。 2025年12月3日，恒瑞医药（600276.SH/01276.HK）宣布提名聘任朱国新为高级副总裁。公开信息显示，加入恒瑞之前，朱国 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant disparities in market valuations between A-shares and H-shares [1][2] - Northeast Electric (00042) leads with a premium rate of 900.00%, while CATL (03750) shows a negative premium rate of -4.93%, suggesting potential investment opportunities and risks [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) with a premium of 900.00% and a deviation value of 34.85% [1] - Hongye Futures (03678) with a premium of 272.56% and a deviation value of 8.87% [1] - Zhejiang Shibao (01057) with a premium of 261.81% and a deviation value of 5.38% [1] - The bottom three stocks with the lowest AH premium rates are: - CATL (03750) with a premium of -4.93% and a deviation value of 6.10% [1] - China Merchants Bank (03968) with a premium of -1.58% and a deviation value of -1.24% [1] - Heng Rui Medicine (01276) with a premium of 0.64% and a deviation value of -2.66% [1] Deviation Value Rankings - The top three stocks with the highest deviation values are: - Guanghetong (00638) with a deviation value of 36.62% [1] - Northeast Electric (00042) with a deviation value of 34.85% [1] - Beijing Machinery (00187) with a deviation value of 27.48% [1] - The bottom three stocks with the lowest deviation values are: - GAC Group (02238) with a deviation value of -20.57% [1] - Jiangsu Ninghu Highway (00177) with a deviation value of -13.89% [1] - Shenzhen Expressway (00548) with a deviation value of -12.04% [1]

Core Viewpoint - FTSE Russell announced adjustments to several indices, including the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, effective after the market close on December 19, 2025 [1][17]. Group 1: Index Adjustments - The FTSE China A50 Index will include Luoyang Molybdenum and Sungrow Power, while removing Jiangsu Bank and SF Holding [3][19]. - The FTSE China 50 Index will add China Hongqiao, CATL, and Heng Rui Medicine, and remove CITIC Securities, Great Wall Motors, and Li Auto [5][21]. - The FTSE China A150 Index will add Ying Shi Innovation, Jiangsu Bank, Huadian New Energy, SF Holding, Jiangbolong, and Huayou Cobalt, while removing Luoyang Molybdenum, Desay SV, Longi Green Energy, Baoxin Software, Shanghai Pharmaceuticals, and Sungrow Power [9][25]. - The FTSE China A200 Index will include Ying Shi Innovation, Huadian New Energy, Jiangbolong, and Huayou Cobalt, and exclude Desay SV, Longi Green Energy, Baoxin Software, and Shanghai Pharmaceuticals [11][27]. - The FTSE China A400 Index will see a broader adjustment, adding Anji Technology, Baiyin Nonferrous Metals, Yitang Co., and BlueFocus, while removing Chipbond Technology, Yipin Hong, Guanghuan Xin, and Huaxi Biological [12][28]. Group 2: Investment Implications - The adjustments by FTSE Russell are expected to attract passive fund allocations to the included stocks and increase overseas interest in Chinese assets [15][31]. - In the first ten months of 2025, foreign capital inflow into the Chinese stock market reached $50.6 billion, significantly surpassing the $11.4 billion for the entire year of 2024, marking an increase of over three times [15][31]. - UBS forecasts that the A-share market will see an increase in earnings growth from 6% this year to 8% next year, driven by improved nominal GDP growth and a narrowing of PPI declines [16][32]. - Morgan Stanley has set a target for the CSI 300 Index at 4,840 points by December 2026, indicating a stable outlook for Chinese stocks amid moderate earnings growth and higher valuation levels [16][32].

Core Viewpoint - Heng Rui Medicine (01276) announced the appointment of Zhu Guoxin as the Senior Vice President, effective from the date of the board meeting approval until the current board's term ends [1] Group 1 - The board of directors approved the proposal for the appointment of a Senior Vice President [1] - The appointment is based on the company's operational development needs [1]

Core Viewpoint - FTSE Russell announced adjustments to several indices including the FTSE China 50 Index, which will take effect after market close on December 19, 2025 [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will exclude companies like CITIC Securities H (06066), Great Wall Motors H (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 孫飄揚先生 中國上海 2025年12月3日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-193 江苏恒瑞医药股份有限公司 第九届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的 ...

Core Viewpoint - FTSE Russell announced adjustments to several indices, including the FTSE China 50 Index, which will take effect after the market closes on December 19, 2025, with changes in constituent stocks [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will remove companies like CITIC Securities H shares (06066), Great Wall Motors H shares (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]